Gba N370S Heterozygous Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Description: Neurons carrying the GBA-N370S heterozygous mutation, associated with increased risk for Parkinson's disease and Lewy body dementia.
The N370S (c.1448T>C, p.N370S) variant in the GBA gene is the most common pathogenic mutation among Gaucher disease patients and is also a significant genetic risk factor for Parkinson's disease (PD). Individuals carrying one copy of this mutation (heterozygous) have a 5-20-fold increased risk of developing PD compared to non-carriers.
The N370S mutation results in:
- Reduced glucocerebrosidase (GCase) enzyme activity (35-40% of normal)
- Impaired lysosomal function
- Accumulation of glucosylceramide
- Enhanced alpha-synuclein aggregation
- Endoplasmic reticulum stress
Neurons carrying GBA-N370S show:
- Impaired autophagy-lysosomal pathway
- Mitochondrial dysfunction
- Increased oxidative stress
- Enhanced vulnerability to alpha-synuclein toxicity
- Altered calcium homeostasis
- iPSC-derived neurons: Patient-derived induced pluripotent stem cells carrying GBA-N370S mutation
- Gene-edited neurons: CRISPR-corrected vs. isogenic GBA-N370S lines
- Primary neuron cultures: Transduced with GBA-N370S constructs
- GBA-N370S neurons exhibit increased accumulation of alpha-synuclein
- Lysosomal dysfunction precedes motor symptoms in carriers
- GCase activity correlates with disease severity
- Autophagy impairment is a central mechanism
- Enzyme enhancement: Small molecules to boost GCase activity (e.g., ambroxol)
- Substrate reduction therapy: Inhibitors to reduce glucosylceramide accumulation
- Gene therapy: AAV-vector delivery of functional GBA
GBA-N370S carriers show distinct biomarkers:
- Reduced GCase activity in cerebrospinal fluid
- Elevated glucosylceramide in plasma
- Specific neuroimaging patterns
The study of Gba N370S Heterozygous Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- GBA mutations in Parkinson's disease (2019)
- Glucocerebrosidase activity and Parkinson's disease risk (2020)
- iPSC models of GBA-Parkinson's disease (2021)
- Ambroxol for GBA-PD clinical trial (2022)